MEDIPOST announced on the 24th that it has obtained the European patent on a culture method that can increase the efficacy of stem cells.
The patent entitled ‘Method for culturing mesenchymal stem cells’ involves techniques to improve culture method and conditions to improve stem cell growth, stem cell capacity, senescence and immune-suppression abilities.
An official from MEDIPOST explained that “this patent technology will improve the stem cells’ ability for regenerating damaged human tissue or suppressing ageing and immunogenicity of cells by strengthening the stemness.”
Furthermore, it was added that “we expect to increase the strengths and competitiveness of the research and development of MEDIPOST’s unique stem cell therapeutics through such stem cell separation, selection, and culture techniques” and added that “in the future, the improved technology will be applied to mass-production of highly-efficient mesenchymal stem cells.”
MEDIPOST has obtained patents for similar technologies in Korea, the United States, China and Japan.
